Literature DB >> 30853807

Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours.

J Zou1, Q Li1, F Kou1, Y Zhu1, M Lu1, J Li1, Z Lu1, L Shen1.   

Abstract

Background: The role of systemic inflammation-based markers remains uncertain in advanced or metastatic neuroendocrine tumours (nets).
Methods: Systemic inflammatory factors, such as levels of circulating white blood cells and other blood components, were combined to yield inflammation-based prognostic scores [high-sensitivity inflammation-based Glasgow prognostic score (hsgps), neutrophil:lymphocyte ratio (nlr), platelet:lymphocyte ratio (plr), high-sensitivity inflammation-based prognostic index (hspi), and prognostic nutritional index (pni)], whose individual values as prognostic markers were retrospectively determined. Univariate and multivariate analyses were used to examine the association of inflammatory markers with overall survival (os).
Results: The study included 135 patients. Univariate analysis revealed that elevated white blood cell count, elevated neutrophil count, low serum albumin, elevated high-sensitivity C-reactive protein, and elevated hspi, hsgps, and nlr scores were significantly associated with worse os. Multivariate analyses demonstrated that, apart from pathology grade and original site of the tumour, elevated hspi (p = 0.004) was an independent prognostic factor for worse os. Conclusions: In the present study, elevated pretreatment hspi was observed to be an independent predictor of shorter os in patients with inoperable advanced or metastatic net. The hspi might thus provide additional guidance for therapeutic decision-making in such patients.

Entities:  

Keywords:  Neuroendocrine tumours; inflammation; overall survival; prognostic indices

Mesh:

Substances:

Year:  2019        PMID: 30853807      PMCID: PMC6380631          DOI: 10.3747/co.26.4135

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  51 in total

1.  Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer.

Authors:  Pengyue Shi; Xue Meng; Mengmeng Ni; Xindong Sun; Ligang Xing; Jinming Yu
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

Review 2.  Consensus on biomarkers for neuroendocrine tumour disease.

Authors:  Kjell Oberg; Irvin M Modlin; Wouter De Herder; Marianne Pavel; David Klimstra; Andrea Frilling; David C Metz; Anthony Heaney; Dik Kwekkeboom; Jonathan Strosberg; Timothy Meyer; Steven F Moss; Kay Washington; Edward Wolin; Eric Liu; James Goldenring
Journal:  Lancet Oncol       Date:  2015-09       Impact factor: 41.316

3.  Nutritional predictors of postoperative outcome in pancreatic cancer.

Authors:  M Kanda; T Fujii; Y Kodera; S Nagai; S Takeda; A Nakao
Journal:  Br J Surg       Date:  2011-02       Impact factor: 6.939

4.  The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer.

Authors:  G Kasymjanova; N MacDonald; J S Agulnik; V Cohen; C Pepe; H Kreisman; R Sharma; D Small
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

5.  A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials.

Authors:  Sumithra J Mandrekar; Steven E Schild; Shauna L Hillman; Katie L Allen; Randolph S Marks; James A Mailliard; James E Krook; Andrew W Maksymiuk; Kari Chansky; Karen Kelly; Alex A Adjei; James R Jett
Journal:  Cancer       Date:  2006-08-15       Impact factor: 6.860

Review 6.  A Systematic Review of the Prognostic Role of Hematologic Scoring Systems in Patients With Renal Cell Carcinoma Undergoing Nephrectomy With Curative Intent.

Authors:  Nathan Grimes; Matthew Tyson; Cathal Hannan; Colin Mulholland
Journal:  Clin Genitourin Cancer       Date:  2016-01-22       Impact factor: 2.872

Review 7.  Review article: the investigation and management of gastric neuroendocrine tumours.

Authors:  R Basuroy; R Srirajaskanthan; A Prachalias; A Quaglia; J K Ramage
Journal:  Aliment Pharmacol Ther       Date:  2014-03-13       Impact factor: 8.171

8.  Neutrophil count is associated with survival in localized prostate cancer.

Authors:  Houda Bahig; Daniel Taussky; Guila Delouya; Amal Nadiri; Ariane Gagnon-Jacques; Paule Bodson-Clermont; Denis Soulieres
Journal:  BMC Cancer       Date:  2015-08-21       Impact factor: 4.430

9.  Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.

Authors:  Jie Li; Ming Lu; Zhihao Lu; Zhongwu Li; Yiqiang Liu; Li Yang; Jian Li; Xiaotian Zhang; Jun Zhou; Xicheng Wang; Jifang Gong; Jing Gao; Yan Li; Lin Shen
Journal:  Oncotarget       Date:  2017-04-11

10.  Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.

Authors:  Suee Lee; Sung Yong Oh; Sung Hyun Kim; Ji Hyun Lee; Min Chan Kim; Ki Han Kim; Hyo-Jin Kim
Journal:  BMC Cancer       Date:  2013-07-22       Impact factor: 4.430

View more
  7 in total

1.  Laboratory variables as predictors of progression in gastroenteropancreatic neuroendocrine tumors in different lines of antineoplastic treatments.

Authors:  Daniela Pezzutti Domigues Armentano; Mariana Ribeiro Monteiro; Pedro Nazareth Aguiar; Jessica Sayuri Tsukamoto; Raquel Baptista Pio; Renata Arakelian; Raphael Leonardo Cunha Araujo; Pedro Luiz Serrano Usón Junior
Journal:  Einstein (Sao Paulo)       Date:  2022-06-01

2.  Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor.

Authors:  Shuai-Shuai Xu; Hua-Xiang Xu; Wen-Quan Wang; Shuo Li; Hao Li; Tian-Jiao Li; Wu-Hu Zhang; Liang Liu; Xian-Jun Yu
Journal:  World J Gastroenterol       Date:  2019-11-07       Impact factor: 5.742

3.  Increased neutrophil-lymphocyte ratio predicts recurrence in patients with well-differentiated pancreatic neuroendocrine neoplasm based on the 2017 World Health Organization classification.

Authors:  Takayuki Miura; Hideo Ohtsuka; Takeshi Aoki; Shuichi Aoki; Tatsuo Hata; Tatsuyuki Takadate; Shimpei Maeda; Kyohei Ariake; Kei Kawaguchi; Kunihiro Masuda; Masaharu Ishida; Masamichi Mizuma; Kei Nakagawa; Takanori Morikawa; Fumiyoshi Fujishima; Takashi Kamei; Hironobu Sasano; Michiaki Unno
Journal:  BMC Surg       Date:  2021-03-31       Impact factor: 2.102

4.  Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma.

Authors:  Jianwei Zhang; Yanshuo Cao; Panpan Zhang; Xiaotian Zhang; Jian Li; Jun Zhou; Xicheng Wang; Zhi Peng; Yu Sun; Jie Li; Lin Shen; Ming Lu
Journal:  Neuroendocrinology       Date:  2021-09-30       Impact factor: 5.135

5.  Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy.

Authors:  Fiona Ohlendorf; Rudolf A Werner; Christoph Henkenberens; Tobias L Ross; Hans Christiansen; Frank M Bengel; Thorsten Derlin
Journal:  Diagnostics (Basel)       Date:  2021-03-12

Review 6.  Serum Inflammation-based Scores in Endocrine Tumors.

Authors:  Pedro Marques; Friso de Vries; Olaf M Dekkers; Márta Korbonits; Nienke R Biermasz; Alberto M Pereira
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 5.958

Review 7.  Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?

Authors:  Elisa Giannetta; Anna La Salvia; Laura Rizza; Giovanna Muscogiuri; Severo Campione; Carlotta Pozza; Annamaria Anita LIvia Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-22       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.